Logo image
Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial (SMART-PDA)
Journal article   Peer reviewed

Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial (SMART-PDA)

Souvik Mitra, Audrey Hebert, Michael P Castaldo, Tim Disher, Walid El-Naggar, Santokh Dhillon, Ziad Alhassen, Jenny Koo, Anup C Katheria, Abbas Hyderi, …
Archives of disease in childhood. Fetal and neonatal edition
05/18/2026
DOI: 10.1136/archdischild-2026-330462
PMID: 42150872

View Online

Abstract

ObjectivesTo assess feasibility of recruitment and compare clinical outcomes in a trial of early selective treatment of a moderate–severe patent ductus arteriosus (PDA) or no intervention in the first 7 postnatal days in extremely preterm infants.DesignMulticentre, open-label, parallel-design pilot randomised controlled trialSettingSeven tertiary/quaternary neonatal intensive care units.PatientsInfants <26 weeks gestational age (GA) with a PDA diagnosed within 72 hours after birth.InterventionsParticipants were randomised to an early echocardiographic screening within the first 72 hours followed by selective medical treatment (SMART) strategy of a moderate–severe PDA shunt or no intervention in the first 7 days.Main outcome measuresThe primary feasibility outcome was the proportion of eligible infants enrolled. Important secondary outcomes included a composite clinical endpoint of survival without major morbidity.Results116 of 185 eligible infants were enrolled (63%, 95% CI 56% to 70%; SMART, n=51, Control, n=53). Of them, 104/116 (90%) (mean GA 24.3 weeks, birth weight 714 g) were randomised. Protocol deviation was 1.9%. Based on the treatment algorithm, 24% infants randomised to SMART never required treatment. Median treatment initiation age in the SMART arm was 2 days (IQR 1–2.5 days). The SMART strategy demonstrated an 85% probability of a better Win ratio (1.34, 95% CrIs 0.73 to 2.5) compared with control.ConclusionsA trial of selective early PDA pharmacotherapy based on clinical and echocardiography grading of PDA shunt volume in the smallest infants is feasible with minimal protocol deviation. Early echocardiography screening and selective pharmacotherapy using the SMART-PDA algorithm may enhance the probability of survival with less morbidities in infants born <26 weeks GA.Trial registration numberNCT05011149.
Cardiology Intensive Care Units, Neonatal Original research

Details

Logo image